StocksTelegraph
S&P 500—NASDAQ—DOW—RUSSELL—
NASDAQ · RNA·Healthcare

Atrium Therapeutics, Inc. Stock Analysis & AI Score

Atrium Therapeutics, Inc. (RNA) has an ST Score of 45.8 (C+), driven by its Forecast (A) and held back by its Growth (F). RNA last traded at $7.98.

Market Open
$7.98
Prev Close
—
Market Cap
—
Day Range
—
52W Range
—
P/E
—
EPS (TTM)
—
Volume
—
Avg —
Beta
—
46
ST Score
45.8/100C+

Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.

As of

AI Daily Briefing

Analysis by AI

RNA Stock Price History

—

RNA Technical Indicators

FMP

Earnings Surprises

Analyst Forecast

Revenue Mix

Company Information

Employees—
CEO—
SectorHealthcare
IndustryBiotechnology
IPO Date—
Website—
Country—
ExchangeNASDAQ

SEC Filings

Annual Report (10-K)

Filing DateAcceptedLink
Loading…

Quarterly Report (10-Q)

Filing DateAcceptedLink
Loading…

Analyst Price Target

ESG Score

RNA Latest Stock News

ST Score

RNA
45.8out of 100
Grade C+

Atrium Therapeutics, Inc. (RNA) has an ST Score of 45.8 (C+), driven by its Forecast (A) and held back by its Growth (F). RNA last traded at $7.98.

Strongest
ForecastA
Weakest
GrowthF
All factor grades
  • ForecastA
  • Financial StrengthA-
  • ProfitabilityB-
  • ValuationC-
  • MomentumD
  • GrowthF
Score methodology

Press Releases

Company Contact Details

RNA stock: frequently asked questions

What is RNA's ST Score?

Atrium Therapeutics, Inc. (RNA) has an ST Score of 45.8 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Is RNA a buy, hold, or sell?

Our ST Score grades it C+ (45.8/100). The ST Score is a data-driven signal, not a recommendation.

What are RNA's factor grades?

Valuation C-, Profitability B-, Financial Strength A-, Momentum D, Growth F, Forecast A.

What is RNA's valuation grade?

Atrium Therapeutics, Inc. (RNA) earns a valuation grade of C-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

What is RNA's growth grade?

Atrium Therapeutics, Inc. (RNA) earns a growth grade of F, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

What is RNA's profitability grade?

Atrium Therapeutics, Inc. (RNA) earns a profitability grade of B-, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

What is RNA's financial strength grade?

Atrium Therapeutics, Inc. (RNA) earns a financial strength grade of A-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.